Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene ...

Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

Q4 2024 Management View CEO Krish Krishnan highlighted 2024 as a strong year, driven by the continued success of the VYJUVEK launch in the U.S., which is tracking as a top-tier rare disease launch. He ...

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

Seonix Bio, a leader in the development of genetic testing for glaucoma, today announced the U.S. launch of SightScore, the first commercially available clinical polygenic risk score testing service ...

Krystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as ...

Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for ...

The genetic disorder cystic fibrosis is unique because it can cause both breathing and digestive problems. Some 40,000 people in the U.S. currently have it, "though this is likely an ...

Vertex Pharmaceuticals dominates the market for cystic fibrosis drugs, but Sionna Therapeutics contends the pharma company’s products still have efficacy and safety limitations. Sionna has ...